Trials / Completed
CompletedNCT00502879
Study Evaluating Etanercept 25mg or 50mg Administered Subcutaneously to Healthy Chinese Male Subjects
A Randomized, Open-Label, Single-Dose Administration, Parallel-Group Study of the Pharmacokinetics of Etanercept, 25mg or 50 mg, Administered Subcutaneously to Healthy Chinese Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to assess the pharmacokinetics of etanercept in healthy Chinese male subjects. Safety and tolerability data will also be obtained.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enbrel (etanercept) |
Timeline
- Start date
- 2007-07-01
- Completion
- 2007-08-01
- First posted
- 2007-07-18
- Last updated
- 2007-12-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00502879. Inclusion in this directory is not an endorsement.